HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antiphospholipid syndrome and palindromic rheumatism: a new possible association.

AbstractOBJECTIVE:
The aim of this study was to report six patients with palindromic rheumatism (PR) in whom signs, symptoms, and/or serologic evidence of antiphospholipid syndrome (APS) developed.
METHODS:
The medical histories of the patients were reviewed with special emphasis on age, gender, duration of PR, and lapse of time until antiphospholipid antibodies were detected or APS was diagnosed. Three representative cases are described.
RESULTS:
Two patients were women and four were men. Their mean age was 49.3 years (range 36-80), and the mean duration of PR was 5.5 years (range 3-8). In all patients, raised titers of antiphospholipid antibodies were found on two or more occasions. Two patients developed clinical pictures compatible with APS, two showed symptoms which may be attributable for APS, and raised titers of antiphospholipid antibodies were found in only two.
CONCLUSION:
It seems that the appearance of these two uncommon conditions together is more than coincidental and may point to a previously unreported clinical association.
AuthorsTatiana Reitblat, Irena Litinsky, Dan Caspi, Ori Elkayam
JournalRheumatology international (Rheumatol Int) Vol. 25 Issue 8 Pg. 595-8 (Oct 2005) ISSN: 0172-8172 [Print] Germany
PMID16189657 (Publication Type: Journal Article)
Topics
  • Adult
  • Aged, 80 and over
  • Antiphospholipid Syndrome (complications, diagnosis)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Rheumatic Diseases (complications, diagnosis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: